Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | TPMT | P51580 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13084370 | 0.87 | MEN1 (0.37) | — | |
| SCHEMBL1656503 | 0.78 | MAPT (0.40) | KIF11CYP3A4 | |
| SCHEMBL2568927 | 0.76 | KCNN4 (0.45) | KIF11CYP3A4SLC22A2SLC22A1SLC22A3 | |
| SCHEMBL6047551 | 0.75 | KCNN4 (0.50) | KIF11 | |
| SCHEMBL4452093 | 0.74 | APP (0.39) | KIF11CYP3A4APP | |
| SCHEMBL4452443 | 0.74 | APP (0.39) | KIF11CYP3A4APP | |
| SCHEMBL4450235 | 0.74 | APP (0.39) | KIF11CYP3A4APP | |
| SCHEMBL13666515 | 0.73 | CNR1 (0.43) | CYP3A4APPTRPV1 | |
| SCHEMBL665034 | 0.71 | APP (0.40) | CYP3A4APPTRPV1 | |
| SCHEMBL17080489 | 0.71 | TRPV1 (0.39) | KIF11APPTRPV1TPMTCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120034270-A1 | S1P Receptors Modulators | AKAAL PHARMA PTY LTD (AU) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034270-A1 | S1P Receptors Modulators | S1PR1, S1PR5, S1PR3 | KIF11 2384/4885CYP3A4 4526/4885IDO1 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.